At a glance
ClinicalIndex Comparison RecordN/ACompleted· 48 enrolled
Drug / intervention
Jalucomplexdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Jalucomplex® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial and Neck Dermal Tissue Defects
In Brief
A clinical study evaluating Jalucomplex for Cicatrix and 2 related conditions. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The Research Question of the present study is the following: in a population of men and women presenting facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects) will linear hyaluronic acid (Jalucomplex®) significantly decrease and / or improve their appearance, results observed after 4 and 8 weeks?
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCicatrix, Lipodystrophy, Plaque
CountriesRomania
CollaboratorsOpera CRO, a TIGERMED Group Company
Timeline
N/ACompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionJul 2022
TodayJul 2026
First PostedFeb 14, 2022
Enrollment StartMar 7, 2022
Primary CompletionJul 7, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.4 years ago
Interventions
Jalucomplexdevice
Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.